Topical corticosteroids have been the default treatment for eczema flares for generations, and for good reason — they work, and they work fast. But long-term steroid use carries real risks (skin thinning, stretch marks, and a rebound phenomenon some patients experience when stopping), which is why the steady arrival of non-steroidal options over the past few years has actually changed how dermatologists manage moderate cases, not just added noise to an already crowded treatment landscape. Here is what is genuinely approved and available right now, versus what is still working through trials.
Difamilast (Adquey): The Newest Approval, February 2026
Difamilast, sold under the brand name Adquey, is the most recent addition to this category — the FDA approved it in February 2026 as a topical phosphodiesterase-4 (PDE4) inhibitor for mild to moderate atopic dermatitis in patients as young as 2 years old. PDE4 inhibitors work by raising cyclic AMP levels inside immune cells, which in turn suppresses the inflammatory signals (including IL-4, IL-13, and TNF-alpha) that drive eczema flares, without the skin-thinning risk that comes with steroids. In Phase 3 trials, a meaningful share of patients reached clear or almost-clear skin by week 4, with itch relief starting early in treatment and application-site reactions occurring at lower rates than with crisaborole, an earlier drug in the same general category.
Roflumilast (Zoryve): The Established PDE4 Option
Roflumilast cream, sold as Zoryve, works through the same PDE4-inhibiting mechanism as difamilast but has been on the market longer — approved in July 2023 for patients 6 and older with mild to moderate atopic dermatitis, with additional approvals for other skin conditions following through 2025. In its Phase 3 INTEGUMENT trials, roughly 28–32% of patients reached clear or almost-clear skin by week 4, with 42–43% reaching a 75% improvement in eczema severity scores, and some patients reporting itch relief within 24 hours. It is applied once daily, which is a real practical advantage over treatments that require twice-daily application for a condition that already asks a lot of patient consistency.
Ruxolitinib (Opzelura): Now Approved Down to Age 2
Ruxolitinib cream, a topical JAK inhibitor sold as Opzelura, received an FDA approval expansion in 2026 that lowered its approved age range to children 2 to 11 years old with mild to moderate atopic dermatitis — a meaningful gap-closer, since prior non-steroid topical options for very young children were more limited. In its TRuE-AD3 trial data, 36.6% of patients on the lower-strength formulation and 56.5% on the higher-strength formulation reached treatment success by week 8, compared with 10.8% on vehicle. Median time to a meaningful reduction in itch scores was 11 to 13 days with ruxolitinib versus 23 days with vehicle — a real, clinically noticeable difference for a symptom that drives most of eczema’s day-to-day misery.
Nemolizumab (Nemluvio): The Systemic Option for More Severe Cases
Not every non-steroid option is topical. Nemolizumab, sold as Nemluvio, is a biologic injection approved for moderate to severe atopic dermatitis in patients whose disease has not responded well enough to topical treatment alone. It works by blocking interleukin-31, a signaling molecule that plays an outsized role in eczema-related itch specifically, which is why it is sometimes described in dermatology coverage as the first itch-targeted biologic for the condition rather than a general anti-inflammatory. It sits in a different treatment category from the topicals above — injectable, prescribed for more severe disease, and typically used alongside a dermatologist’s ongoing monitoring rather than as a first-line option.
What This Actually Costs
Brand-name topical non-steroids (Zoryve, Opzelura, Adquey) commonly list at $600–$900+ for a tube without insurance, though manufacturer copay programs frequently bring out-of-pocket costs down to $0–$50 per month for insured patients who qualify. Generic prescription steroids, by comparison, can cost as little as $10–$30 without insurance — part of why steroids remain the practical first choice for many flares even as non-steroid options expand. Biologics like Nemluvio are priced closer to $2,000+ per month list price, almost always billed through insurance with prior authorization, not paid out of pocket.
Why the Age Range Keeps Coming Up
A recurring theme across these approvals is how much attention regulators and manufacturers are putting specifically on younger patients. Difamilast’s approval down to age 2 and ruxolitinib’s 2026 expansion to ages 2 to 11 both close gaps that used to leave parents of young children with eczema choosing between steroids and comparatively little else non-steroidal. That is not a coincidence — pediatric eczema is common, chronic steroid exposure in a growing child is a legitimate long-term concern for parents and pediatric dermatologists alike, and the clinical trial requirements for pediatric approval are genuinely more rigorous than for an adult-only indication, which is part of why these approvals have trailed the adult versions of the same drugs by a year or more in most cases.
Frequently Asked Questions
Do these replace steroids completely?
Not for most patients. Dermatologists generally use non-steroid topicals for maintenance, sensitive areas (face, skin folds, eyelids), or long-term use where steroid risk accumulates, while still reaching for a short steroid course during an acute flare. The two categories are usually used together over time, not as a strict either/or choice.
Is a PDE4 inhibitor the same as a JAK inhibitor?
No — they are different drug classes with different mechanisms, even though both are marketed as non-steroidal. PDE4 inhibitors (roflumilast, difamilast) work through cyclic AMP signaling; JAK inhibitors (ruxolitinib) block a different inflammatory signaling pathway and carry their own separate set of prescribing considerations, including a boxed warning specific to the JAK inhibitor class as a whole.
How do I know which one is right for my eczema?
That is a conversation for a dermatologist, not a self-selection based on which is newest. Age, disease severity, which body areas are affected, and insurance formulary coverage all factor into which non-steroid option (if any) makes sense before steroids.
Why would a doctor still choose a steroid over one of these newer options?
Cost and speed are the two most common reasons. Generic steroids are inexpensive and act quickly on an acute flare, while several of the newer non-steroid options carry meaningfully higher list prices and, in some cases, a slower onset of visible improvement, even when their long-term safety profile is more favorable for repeated or prolonged use.
Final Thoughts
Eczema treatment has genuinely diversified in the past two years, not just in name-brand count but in actual mechanism — PDE4 inhibition, JAK inhibition, and IL-31 blockade are three distinct approaches now available where steroids were once close to the only non-prescription-strength option. None of them make steroids obsolete, and none of them should be started without a clinician’s input, especially for young children.
For more on evidence-based skin treatments and what the research actually supports, visit the Skincare section at gemifys.com.
